Control of Chemicals Ordinance (Amendment of Schedule 2) Order 2022
- Notifying member
- Hong Kong, China
- Title
- Control of Chemicals Ordinance (Amendment of Schedule 2) Order 2022
- First published
- 20/10/2022
- First EIF
- 16/12/2022
- Latest published
- In force to
- Latest notification
- G/LIC/N/3/HKG/27
- Product categories
- List of products subject to licensing
- Nature of licensing
- Administrative purpose/measure being implemented
- Administrative body(ies) for submission of applications
-
- Contact point for information on eligibility
-
Same as the "Administrative bodies"
- Expected duration of licensing procedure
- Found by secretariat
- No
- Related document symbols
-
- G/LIC/N/2/HKG/22
- Source
- Notes
-
-
G/LIC/N/2/HKG/22
From 16 December 2022, three substances (i.e., 4-anilinopiperidine, tert-butyl 4-(phenylamino)piperidine-1-carboxylate, and norfentanyl) added to the control under the Control of Chemicals Ordinance.
The amendments aimed to deter the trafficking and abuse of these dangerous drugs and substances and
help fortify Hong Kong's defence in the fight against drugs.
Modification of specific details in existing procedures: Product coverage
From 16 December 2022, nine substances (i.e., brorphine, clonazolam, CUMYL-PEGACLONE, diclazepam, diphenidine, flubromazolam, isotonitazene, MDMB-4en-PINACA, and metonitazene) have been put under the same strict control as other dangerous drugs under the Dangerous Drugs Ordinance ("DDO"); and three substances (i.e., 4-anilinopiperidine, tert-butyl 4-(phenylamino)piperidine-1-carboxylate, and norfentanyl) added to the control under the Control of Chemicals Ordinance. Also, from 1 February 2023, CBD has been put under the same strict control as other dangerous drugs under the DDO. Hong Kong Harmonized System (HKHS) codes of the concerned substances are tabulated in the Annex of this notification. The amendments aimed to deter the trafficking and abuse of these dangerous drugs and substances and help fortify Hong Kong's defence in the fight against drugs.
-